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Leukotrienes are a  novel group of chemical mediators generated by the oxidation 
of arachidonic acid by the lipoxygenase pathway (for reviews see 1, 2). One chemical 
pathway  of leukotriene  synthesis  from arachidonic acid  results  in  the  formation of 
dihydroxy derivatives, which include leukotriene B4 (LTB4; 5-(S),  12-(R)-dihydroxy- 
6-cis-8,10-trans-14-ds-eicosatetraenoic  acid) 1  (3)  and  its  isomers  (5-(S),  12-(R)-dihy- 
droxy-6,8, lO-trans- 14-ds-eicosatetraenoic  acid (abbreviated 5-(S), 12-(R)-6-trans-LTB4) 
and 5- (S),  12- (S)-dihydroxy-6,8,1 O-tram- 14-cis-eicosatetraenoic acid (abbreviated 5- (S), 
12-(S)-6-trans-LTB4)  (4).  LTB4 has potent chemotactie and chemokinetic activity for 
leukocytes  (5, 6);  in addition,  recent evidence suggests that  it  induces the release of 
thromboxanes and prostaglandins from pulmonary tissue  (7). 
A  second pathway of leukotriene  synthesis results  in the formation of agents that 
cause increased vascular permeability  and smooth muscle contraction  (8-10). These 
agents, called slow reacting substance  (SRS), are generated  in immediate hypersen- 
sitivity reactions and are thought to play an important role in asthma through their 
potent  bronchiolar  smooth  muscle  contracting  activity.  The  first  SRS  that  was 
structurally identified was leukotriene C4 (LTC4; 5-(S)-hydroxy-6-(R)-S-glutathionyl- 
7,9-trans-ll,14-cis-eicosatetraenoic  acid)  (11-13).  The removal of glutamic acid from 
LTC4 by y-glutamyl transpeptidase  results  in  the  formation of the cysteinylglycine 
derivative  leukotriene  D4  (LTD4;  5-(S)-hydroxy-6-(R)-S-cysteinylglycine-7,9-trans- 
11,14-cis-eicosatetraenoic  acid), which also has potent  SRS activity  (14-17).  Leuko- 
t riene  E4  (LTF_~;  5- (S)-hydroxy-6-  (R)-S-cysteinyl- 7,9-trans- 11,14-cis-eicosatetraenoic 
acid)  is  formed  on  the  removal  of glycine  from  LTD4  through  the  action  of an 
aminopeptidase (16, 17). Stereoisomers of LTC4 and LTD4 that possess 11-tram double 
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bonds  (11-trans-LTC4  and  11-trans-LTD4,  respectively)  are also  formed  (1,  18).  The 
SRS activity of biological fluids is due predominantly to LTC4 and LTD4 (1, 2). 
Leukotriene  generation  by mastocytoma cells  (11),  basophils  (14,  15,  17),  macro- 
phages  (19-22),  neutrophils  (3,  4),  and  human  lung tissue  (23)  has been  described; 
their formation by eosinophils, an important participant in immediate hypersensitivity 
reactions,  however,  has  not  been  previously  reported.  We  report  here  that  horse 
eosinophils stimulated with the calcium ionophore A23187 generate LTB4, 5-(S),  12- 
(R)-6-trans-LTB4,  5-(S),  12-(S)-6-trans-LTB4,  LTC4,  11-trans-LTC4, and LTD4. 
Materials  and Methods 
Special Reagents.  Leukotriene standards  were obtained  as  follows.  LTB4,  5-(S),  12-(R)-6- 
trans-LTB4 and 5-(S),  12-(S)-6-trans-LTB4 were isolated from A23187-stimulated human neu- 
trophils  (3, 4);  LTC4,  11-trans-LTC4  and LTD4 were isolated from A23187-stimulated mouse 
mastocytoma cells (11,  15); synthetic LTC4 and LTD4 were kindly provided by Dr. J. Rokach, 
Merck Frosst Laboratories, Pointe-Claire/Dorval, Quebec (24); 3H-LTC4 from mouse peritoneal 
macrophages was the gift of Dr. C. A. Rouzer and Dr. W. A. Scott, The Rockefeller University, 
New York (21). 
The  SRS  antagonist  FPL  55712  was  kindly  provided  by  P.  Sheard,  Fisons  Limited, 
Pharmaceutical  Division,  Loughborough, England;  5,8,11,14-eicosatetraynoic  acid  (ETYA) 
was provided by Dr.  W. E. Scott, Hoffmann-LaRoche, Inc., Nut|ey, N. J.; and the calcium 
ionophore A23187 was provided by Dr. J. Hosley, Lilly Research Laboratories, Indianapolis, 
Ind. Arachidonic acid, soybean lipoxygenase (type I), histamine diphosphate,  indomethacin, 
fl-nicotinamide adenine dinucleotide, reduced form (fl-NADH), pyruvic acid (sodium salt, type 
II), lactate  dehydrogenase (LDH), and  polyvinylpyrrolidone (40,000  tool wt)  were obtained 
from Sigma Chemical Co., St. Louis, Mo., and Amberlite XAD-7 was obtained from Mallink- 
rodt Chemical Works, St. Louis, Mo. [1-14C]arachidonic  acid (>50 mCi/mmol) was obtained 
from Amersham Corp., Arlington Heights, Ill. 
Isolation of Eosinophils.  Eosinophils were isolated  from  10-40 liters  of horse blood  (kindly 
provided by the Florence Packing Co., Florence, Wash.), as previously described (25). In brief, 
after 1 h of spontaneous sedimentation, the leukocyte-rich plasma and the upper quarter of the 
erythrocyte sediment  were  collected  and  centrifuged  at  3,500 g  for  15  min  at  20°C.  The 
eosinophils  penetrated  into  the  erythrocyte  pellet  during  this  centrifugation,  whereas  the 
remaining leukocytes formed a burly coat layer at the cell-plasma interface. The burly coat and 
platelet-containing  plasma were removed by aspiration.  Polyvinylpyrrolidone sedimentation 
followed  by  hypotonic  lysis  enabled  a  complete  separation  of the  erythrocytes  from  the 
eosino~hils.  The eosinophils were washed with 1% NaCI and resuspended at a concentration of 
5 ×  10  cells/ml in a standard salt solution, pH 7.2, consisting of 154 mM NaC1, 2.7 mM KC1, 
4 mM Na2HPO4, 2.7 mM KH2PO4, 0.9 mM CaCI2, 0.8 mM MgSO4, and 6 mM glucose.  The 
cell preparations consisted of98-100% eosinophils (<2% neutrophils), which were >98% viable 
as measured by trypan blue exclusion. 
Isolation of Neutrophils.  Neutrophils were isolated from horse blood as follows. 30 ml of a  1:3 
blood: 0.9% NaC1 mixture was layered over 12 ml of Hypaque-Ficoll (specific gravity 1.0775) 
and  the  tubes  centrifuged  at  1,000  g  for  40  min  at  20°C.  The  upper  layer,  containing 
mononuclear cells, was removed by aspiration. The lower layer, containing polymorphonuclear 
leukocytes and erythrocytes, was mixed with 3% PVP (in 0.9% NaC1) and platelet-free horse 
plasma  in  a  3:2:1  mixture  and  allowed  to sediment  for 40  min  at  4°C.  The  upper  layer, 
containing neutrophils, was aspirated, and the cells were collected by centrifugation. Remaining 
erythrocytes were removed  by  hypotonic lysis,  and  the  neutrophils  were suspended  in  the 
standard salt  solution. The neutrophil  preparations were of >98% purity (1-2% eosinophils) 
and were >97% viable by trypan blue exclusion. 
SRS and LDH Release.  Duplicate samples of eosinophils or neutrophils were preincubated 
for 5 min at 37°C in standard salt solution, pH 7.2, in the presence and absence of arachidonic 
acid or inhibitors of arachidonic acid metabolism (see legends to figures and tables) in a water 
bath  oscillating 80 times  per  min.  The ionophore A23187 was then  added  to make a  total 392  LEUKOTRIENE  GENERATION  BY EOSINOPHILS 
volume of 1.0 ml. Unless otherwise indicated, incubations  were for 15 min at 37°C, after which 
the  suspensions were  placed  on  ice  until centrifugation at  400 g  for  6  min at  4°C.  The 
supernatants and pellets were stored at -70°C until hioassay of SRS activity or measurement 
of LDH activity. 
SRS Bioassay.  SRS activity was  assayed on the atropinized, antihistamine-treated guinea 
pig ileum, as  previously described  (26),  using the  model ABAC-100, Automatic Bio-Assay 
Controller, (ADAPS, Inc., Dedham, Mass.).  1 unit of SRS  is defined as  the concentration 
required to produce an ileal contraction equal in amplitude to that produced by 5.0 ng/ml 
histamine base. Peak contractions were measured 2 rain after addition of the samples. Varying 
concentrations of FPL 55712 were added to the 7.0-ml bioassay chamber to test for inhibition 
of SRS-induced contractions (27). The reaction mixture was  diluted at least 200-fold  before 
application in the guinea pig ileal bioassay. None of the individual  reaction mixture components 
(e.g.,  A23187,  indomethacin, ETYA)  caused  ileal  contraction or  affected  the  contraction 
induced by synthetic LTC4 or LTD~ under the conditions used. 
Measurement of LDH Release.  LDH was measured using/~-NADH as substrate, as previously 
described (28). 
Purification ofEosinophil  Leukotrienes. Column Chromatography.  Eosinophils (3 ×  l0  s in 27 ml of 
the standard salt solution) were preincubated for 5 min at 37°C in a shaking water bath. The 
ionophore A23187  (10/~g/ml, final concentration) was then added to make a  total reaction 
volume of 30 ml and a  final cell concentration of 107 cells/ml. After 15 min, the cells were 
pelleted at 400 g for 10 rain at 4°C and discarded. The cell-free supernatant was adjusted to 
80% ethanol (vol/vol). After storage for 16-20 h at 4°C, the ethanol suspension was centrifuged 
at  3,000  g  for  10  min at  4°C,  and  the  pellet  was  discarded.  The  clear  supernatant was 
evaporated to dryness in vacuo at 30-45°C in a Buchler flash evaporator (Buchler Instruments 
Division, Searle Analytic, Inc., Fort Lee, N. J.). The SRS-containing residue was resuspended 
in 5.0 ml of 0.1 M NaOH, incubated for 30 min at 37°C, adjusted to pH 5.0, and applied over 
60 min to an Amberlite XAD-7 column (1.0 ×  30.0 cm), previously washed with  1 liter of 
acetone and 1 liter of distilled water. The column was washed with 300 ml distilled water, and 
elution was performed with 300 ml of 100% ethanol. The ethanol eluant was evaporated in 
vacuo and stored at -70°C (26). 
In some experiments, eosinophils were preincubated with radiolabeled arachidonic acid. [ 1- 
14C]arachidonic  acid (150 #g; 24/~Ci)  in a total volume of 0.9 ml was evaporated to dryness, 
redissolved in 0.1 ml ethanol, and added to the eosinophil preparation. After preincubation for 
30 min at 37°C, A23187 was added, and the sample was treated as described above. 
Reverse-Phase High-Pressure Liquid  Chromatography (HPLC).  The dried eluant from the Am- 
berlite XAD-7 column was resuspended in 300 #1 of methanol/water (65:35, vol/vol), containing 
0.1% acetic acid  (final pH,  3.9),  centrifuged at  3,000 g  for  15  min at  20°C, and the clear 
supernatant applied to a 3.9 X 300-mm #Bondapak Cls column (10 #m particle size) (Waters 
Assoc., Milford, Mass.).  Elution was with the same solvent at a now rate of 1.0 ml/min and a 
pressure of 1,600 P.S.I., using either a Waters model ALC 244 or model 334 MP (Beckman 
Instruments, Inc., Berkeley, Calif.) HPLC apparatus. The optical density of the column eluant 
was continuously  recorded at 280 nm, and sequential 1-ml fractions were collected for assay of 
SRS activity. After 40 rain of isocratic elution, a linear methanol gradient from 65 to 100% was 
applied  to  the  column  to  remove  all  absorbed  lipids.  Biologically active  fractions  were 
evaporated to dryness under nitrogen and resuspended in a small volume of the methanol/ 
water/acetic acid solvent. To obtain chromatographically pure compounds, each sample was 
rechromatographed at least twice, either as described above or on a 4.6 ×  250-ram Ultrasphere 
ODS Cls column (5 #m particle size; Altex Scientific Co., Berkeley, Calif.) with a mobile phase 
of methanol/water (72:28, vol/vol) with 0.1% acetic acid, pH 3.9, and a flow rate of 1 ml/min. 
For identification, the samples underwent additional rechromatography on each of the two 
columns described above and on a 4.6 ×  250-ram Nucleosil Cls, 5/~m particle size column 
(Machery-Nagei, Diiren, West Germany) with a methanol/water (65:35, vol/voi) 0.01% acetic 
acid, pH  5.7,  mobile phase and a  flow  rate of 1.5  ml/min, and their retention times were 
compared to those of appropriate standards. 
Ultraviolet Spectrometry.  The UV spectra of the rechromatographed compounds were deter- 
mined using a  Cary 219  spectrophotometer  (Cary Instruments, Monrovia, Calif.).  In some JORG ET AL.  393 
experiments the measurements were made before and after incubation of the compound in the 
standard salt solution with soybean lipoxygenase (10 #g/ml) for 30 rain at 20°12 (11). 
Gas Chromatography-Mass Spectrometry.  Compounds that co-eluted on HPLC with the LTB4, 
5-(S), 12-(R)-6-trans-LTB4  and 5-(S), 12-(S)-6-trans-LTB4  standards were derivatized by meth- 
ylation with diazomethane and trimethylsilylation with bis(trimethyl)trifluoroacetomide.  De- 
rivatives  were  analyzed  by gas  chromatography-mass spectrometry  using  a  Finnigan  3200 
quadrupole mass spectrometer (Finnigan Corp., Sunnyvale, Calif.)  under electron impact (70 
eV) conditions. Gas chromatographic separation was performed using 3% OV-101 on Supel- 
coport (140-160 mesh) in a glass column 0.2 ×  150-cm and temperature programming 240 ° to 
280  °  at 8°/min.  Equivalent chain length was determined by coinjecting reference fatty acid 
methyl esters,  as previously described (29). 
Statistical Analysis.  The data are reported as the mean ±  SE of the combined experiments. 
Differences were analyzed for significance using Student's  two-tailed  t  test  for independent 
means (not significant, P >  0.05). 
Results 
Incubation of eosinophils with the calcium ionophore A23187 results in the release 
into the extracellular  medium of an agent or agents that induces contraction of the 
guinea pig ileum.  The characteristics  of that  contraction are those of SRS--a  slow, 
sustained  contraction  in  the  presence  of atropine  and  an  antihistamine.  Further, 
contraction  was  inhibited  by  the  SRS  antagonist  FPL  55712.  The  concentration 
necessary  to  produce  a  50%  reduction  of the  guinea  pig  ileal  contractile  response 
(ICs0) was ~ 11  ng/ml  (Table I), which is consistent  with the concentrations of FPL 
55712 reported to block 50% of the activity of the SRS obtained from guinea pig lung 
(27),  rat  basophilic  leukemia  cells  (30),  and  rat  peritoneal  mast  cells  (31).  Other 
smooth  muscle  stimulants,  such  as  prostaglandins,  serotonin,  and  bradykinin,  are 
considerably less sensitive to FPL 55712: the ICs0 for these stimulants  is  1,000 times 
greater than that for SRS (27). This suggests that most if not all of the smooth muscle 
contracting activity released from eosinophils by A23187 is due to SRS. 
SRS production by eosinophils  (5 ×  106 cells/ml)  increased with A23187 concen- 
tration  to reach a  maximum at  10 #g/ml  (1.9 ×  10  -5 M)  (Fig.  1) with LDH release 
<5% at these concentrations. When the ionophore concentration was raised to 20 #g/ 
ml (3.8 ×  10  -5 M),  SRS formation decreased and LDH release increased, suggesting 
cytotoxic injury to the cells. Unless otherwise indicated, the ionophore concentration 
used  was  10 #g/ml.  SRS release  was evident  1 min after  the addition  of ionophore 
and  increased  with  time  to  reach  a  maximum  at  15-30  rain  (data  not  shown). 
Incubation for 15 min at 37°C was routinely used. 
TAnLE I 
Inhibition of Eosinophil SRS Activity by FPL 55712 
FPL 55712  Inhibition of SRS activity 
ng/ml  % 
7  34.7 + 5.6 (5) 
14  62.3 -¢- 4.1 (5) 
28  73.9 + 3.3 (3) 
Supernatants  from ionophore-treated eosinophils were diluted with standard 
salt solution to yield 1-2 units of ileal contracting activity per ml. FPL 55712 
was added at the final concentrations indicated, and the percent inhibition of 
gut  contraction  was  determined.  The  results are  the  mean  :1: SE  of (n) 
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Fxc.  1.  Effect  of ionophore concentration on SRS generation by eosinophils. The reaction mixture 
contained 5 ×  10  n eosinophils and the calcium ionophore A23187  at the concentrations indicated in 
1.0 ml of the standard salt solution. SRS (0--- ---0) and LDH (O  O) release above background 
is shown. The background SRS release was 0.2  ±  0.1  units, and LDH release was 2.1  ±  0.8%. The 
results are the mean ±  SE of five experiments. 
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Fic.  2.  Comparison of eosinophil and neutrophil SRS generation. The reaction mixture contained 
eosinophils (0----0)  or neutrophils (0  O) in the numbers indicated,  10/~g  A23187,  and the 
standard salt solution to a final volume of 1.0 ml. Incubation was for 15 min at 37°C. LDH release 
was <5% at all  cell concentrations and with both cell types. The results are the mean ±  SE of five 
experiments. 
Because SRS is also a product ofneutrophil stimulation by A23187, the contribution 
of the  1-2%  neutrophil  contamination  of the  eosinophil  preparations was assessed. 
Fig. 2 compares SRS release by horse neutrophils (98% pure) to that of the eosinophil 
preparation over a  range of cell concentrations  from 2.5  ×  106 to 25  ×  106 per ml. 
SRS  generation  by the  eosinophil  preparations  was  four  to  five times  that  of the 
neutrophil preparations at all cell concentrations, suggesting that neutrophils do not 
contribute significantly to the SRS generated by the eosinophil preparations. 
The effect of arachidonic acid or inhibitors of araehidonic acid metabolism on SRS JORG ET AL.  395 
production  by eosinophils  is shown in Table II. Arachidonic acid at  3.0 #g per ml 
increased  A23187-induced  SRS release  31.5%,  whereas  lower  (0.3 #g/ml)  or higher 
(30.0 #g/ml) concentrations had no significant effect. ETYA, an inhibitor of both the 
cyclooxygenase  and  lipoxygenase  pathways  of arachidonic  acid  metabolism  (32), 
significantly inhibited A23187-induced eosinophil SRS production at concentrations 
of 10 and  100 #g per ml, whereas indomethacin,  a  selective inhibitor of the cycloox- 
ygenase pathway (32), increased SRS production at a concentration of 1.0 #g per ml. 
In each of eight experiments,  3  ×  10  s eosinophils were suspended in 30 ml of the 
standard salt solution and stimulated with 10 #g/ml A23187. After ethanol extraction 
and  Amberlite  XAD-7  chromatography,  the  components  of the  preparation  were 
separated  by  HPLC.  Fig.  3  demonstrates  a  typical  elution  pattern  of the  280  nm 
absorbing material.  Five 280-nm absorbing peaks with elution times between  11 and 
26 min  (designated  I  to V)  were  found to have SRS activity.  All compounds were 
radiolabeled when stimulation of eosinophils by A23187 was performed in the presence 
of [t4C]arachidonic acid. The SRS ileal contracting activity of compounds I, II, and 
III were not blocked by FPL 55712, whereas  11  ng/ml FPL 55712 produced a  50% 
reduction of contractions induced by compounds IV and V. Other characteristics  of 
compounds I to V  are indicated below. 
Compound I.  Compound I, which accounted for  1.8%  of the total eosinophil SRS 
activity,  had  a  retention  time  of  11.9  min  under  our  standard  HPLC  conditions 
(Table III). Its UV spectrum was characterized by a peak at 269 nm and two smaller 
peaks  at  259  and  280  3=  1  nm  (Fig.  4A).  The  methyl  ester,  trimethylsilylether 
derivative  had  an  equivalent  carbon  number  of 25.0  by gas  chromatography  and 
diagnostic  ions  at  M/A  479  (M-15),  404  (M-90),  383,  293,  217,  203,  and  129. 
Compound I  co-eluted with  5-(S),  12-(R),  6-trans-LTB4  under each of three  HPLC 
conditions. 
Compound II.  Compound II accounted for 2% of the total eosinophil SRS activity 
TABLE II 
Effect of Arachidonic Acid and Arachidonic Acid Inhibitors on SRS Release by 
Eosinophils 
Supplements  SRS 
units 
None  55.8 + 3.8 
Arachidonic acid (30.0 #g/mt)  53.0 3= 5.1 
Arachidonic acid (3.0 #g/ml)  69.7 3= 3.5 <0.05 
Arachidonic acid (0.3 #g/ml)  58.1 3= 3.8 
ETYA (100.0 #g/ml)  2.7 3= 1.2 <0.001 
ETYA (10.0 lag/ml)  32.3 3= 5.4 <0.01 
ETYA (1.0 #g/ml)  49.1 3= 2.8 
ETYA (0.1 #g/ml)  56.7 4- 7.2 
Indomethacin (I0.0 #g/ml)  58.0 3= 2.9 
Indomethacin (1.0 #g/ml)  71.8 3= 3.1 <0.02 
Indomethacin (0.1 #g/ml)  65.4 4- 3.6 
Eosinophils (5 ×  10  e) in 1.0 ml of the standard salt solution were preincubated 
with the supplements at the concentrations indicated for 5 min at 370C, after 
which 10 #g/ml of A23187 was added. SRS release was determined after an 
additional  15 rain of incubation.  Probability values for the difference from 
eosinophils plus A23187 alone (none) are shown where significant, The results 
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FIG.  3.  Reverse-phase  HPLC chromatogram ofeosinophil SRS. Elution pattern ofeosinophil SRS 
using a gBondapak Cls column with methanol/water (65:35, vol/vol) and 0.1% acetic acid, pH 3.9, 
as the solvent. Absorbance was determined at 280 nm, and each 1-ml fraction was assayed for SRS 
activity. 
TABLE  III 
HPLC Retention Times and SRS Activity of Rechromatographed  Eosinophil 
Compounds 
Retention time 
Compound  SRS activity 
A  B  C 
rain  % of total 
I  11.9  16,8  15.3  1.8 
II  13.4  19.2  16.7  2,0 
III  14.8  22.2  18.0  3.4 
IV  16.4  33.l  6.7  66.0 
V  24.9  42.4  15.8  26.8 
The retention  times of the rechromatographed  eosinophil  compounds were 
compared  in  three  different  HPLC  systems:  Column  A:  3.9  ×  300-ram, 
~Bondapak  Cxa  (10 btm  particles);  solvent,  methanol/water  (65:35, vol/vol) 
with 0.1% acetic acid, pH 3.9; flow rate,  1.0 ml/min. Column B: 4.6 X 250- 
mm Ultrasphere ODS C1s (5/zm particles);  solvent,  methanol/water (72:28, 
vol/vol) with 0.1% acetic acid, pH 3.9; flow rate,  1.0 ml/min. Column C: 4.6 
×  250-mm,  Nucleosil  CIS (5 ~m particles);  solvent,  methanol/water  (65:35, 
vol/vol) with 0.01% acetic acid, pH 5.7; flow rate, 1.5 ml/min. The results are 
the mean of eight experiments. 
and  had  a  retention  time of 13.4  min  under  our standard  HPLC  conditions  (Table 
III). It had the same UV  spectrum  (Fig. 4A)  and identical gas chromatography-mass 
spectral characteristics as compound  I. Compound  II co-eluted on each HPLC  column 
with 5-(S),  12-(S)-6-trans-LTB4. 
Compound III.  Compound  III  accounted  for  3.4%  of  the  total  eosinophil  SRS 
activity  and  had  a  retention  time  of  14.8  rain  on  our  standard  HPLC  conditions 
(Table III). Its UV  spectrum was characterized by a  peak at 270 nm, with two smaller 
peaks  at  260  and  281  -+  1  nm  (Fig.  4B).  Gas  chromatography  of  the  derivative 
indicated  an equivalent carbon  number  of 23.5,  and  its mass  spectral  characteristics 
were identical  to that  of authentic  LTB4.  Compound  III co-eluted with  LTB4 under 
each of three HPLC  conditions. J()RG  ET  AL.  397 
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FiG. 4.  Ultraviolet spectra of rechromatographed eosinophil  SRS fractions.  (A), compound I; (B), 
compound III; (C), compound IV before (  ) and after (----) incubation with soybean  lipoxy- 
genase.  Compounds were dissolved  in methanol/water (65:35, vol/vol) with 0.1% acetic acid, pH 
3.9. 
Compound IV.  Compound IV, the predominant eosinophil SRS, as measured by 
bioactivity  (66%  of the  total  SRS),  had  a  retention  time  of  16.4  min  under  our 
standard  HPLC conditions  (Table III,  Fig.  5).  Its UV absorption spectrum  had  a 
peak at 280 nm, with shoulders at 270 and 292 +  1 nm (Fig. 4C), which is consistent 
with  a  sulfur substituent  a  to a  conjugated  triene  (33).  The  absorption  spectrum 
shifted to a peak at 308 nm on incubation of compound IV with soybean lipoxygenase; 
this enzyme also decreased the ileal contracting activity of compound IV by >90%. 
Compound IV co-eluted on HPLC with LTC4 obtained from mouse mastocytoma 
cells  and  peritoneal  macrophages  and  also  with  synthetic LTC4  (Fig.  5).  A  small 
amount  of 11-trans-LTC4 was  found eluting  closely after the  eosinophil  LTC4 on 
rechromatography. 
Compound V.  Compound V  accounted for 26.8% of the eosinophil SRS  activity 
and had a  retention time of 24.9 min under our standard HPLC conditions (Table 
III). It had the same absorption spectrum (Fig. 4 C) and response to lipoxygenase as 
did compound IV. Compound V  co-eluted with synthetic and mouse mastocytoma 
LTD4 on each of the HPLC columns. 
From these findings we conclude that  compound I  is  5-(S),  12-(R)-6-trans-LTB4; 
compound II is 5-(S),  12-(S)-6-trans-LTB4;  compound III is LTB4; compound IV is 398  LEUKOTRIENE  GENERATION  BY  EOSINOPHILS 
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Fio.  5.  HPLC identification of compound IV. Re,  chromatography of (A) synthetic LTG4 and (B) 
compound IV on pBondapak Cls (10/tm particles) with methanol/water (65:35, vol/vol) and 0.1% 
acetic acid, pH 3.9, at a flow rate of 1.0 ml/min. [14C]arachidonic  acid cpm (~) of sequential 0.5- 
min aliquots of a similarly rechromatographed sample of compound IV are shown. 
LTC4; and compound V  is LTD4. The final yield of each compound from 3 ×  l0  s 
eosinophils was 0.7 pg for compound I, 0.8/~g for compound II, 1.1/~g for compound 
III, 3.6 pg for compound IV, and 0.3 #g for compound V, as determined from their 
UV  spectra,  using  the  reported  extinction  coefficients for  each  of the  identified 
leukotrienes (3, 4,  13, 23). This is an underestimate of the total production because it 
does not take into account the recovery during the isolation procedures. Beginning 
with 25,400 SRS units per 3 ×  10  s eosinophils in the initial supernatant, we recovered 
10,500 SRS units in the final HPLC eluates, a recovery of 41%. Horse neutrophils (3 
×  10  a)  treated  in an  identical fashion yielded 0.8 pg of LTC4, which corresponds 
closely to the lower SRS activity produced by neutrophils compared to eosinophils 
shown in Fig. 2. 
Discussion 
Our data indicate that horse eosinophils can metabolize arachidonic acid by the 
lipoxygenase pathway to  form leukotrienes with potent  SRS  activity.  Eosinophils 
highly purified to >98% were found to generate FPL 55712-inhibitable SRS activity 
without release of appreciable LDH when stimulated with 10 ~g/ml of the calcium 
ionophore A23187. 
Horse eosinophils generated up  to  five times the  amount  of SRS  produced  by 
similarly treated horse neutrophils when compared on a  per cell basis. Thus, of the 
~138  units of SRS  bioactivity generated by 25.0  ×  10  e eosinophils, <1  SRS  unit 
could be attributed to neutrophil contamination  (2% neutrophils each with % the 
activity on  a  per  cell  basis).  Leukocyte preparations  consisting predominantly of 
neutrophils when incubated with 1-10/tg/ml ionophore A23187 generate SRS  (34) 
and leukotrienes (3-5). Because these preparations contained a variable proportion of 
eosinophils, eosinophil contribution to the leukotriene generation may be significant. 
The inhibition of eosinophil SRS release by ETYA and augmentation of its release JORG  ET  AL.  399 
by araehidonic acid and indomethacin are consistent with other reports (I 1, 35) that 
SRS is a lipoxygenase product of arachidonic acid. This was confirmed by separation 
and identification of specific leukotrienes.  Leukotrienes were isolated in pure form by 
Amberlite XAD-7 and repeated HPLC chromatography. Individual compounds were 
identified by comparison of their retention times on  HPLC under three different 
conditions to  authentic standards,  by  their  characteristic  ultraviolet spectra  and 
spectral shift after treatment with soybean lipoxygenase,  by their incorporation of 
[a4C]arachidonic acid, and by gas chromatography and mass spectrometry as indicated 
in the text. The eosinophil products by these criteria were 5-(53, 12-(R)-6-trans-LTB,. 
5-(53, 12-(S)-6-trans-LTB4, LTB4, LTC4, 11-trans-LTC,, and LTD4. A23187-stimulated 
human  eosinophils  obtained  from  patients  with  the  hypereosinophilic syndrome 
produced the same leukotrienes (5-(S), 12-(R)-6-trans-LTB,, 5-(53, 12-(S)-6-trans-LTB,, 
LTB4, LTC4, and LTD4) as did horse eosinophils. 2 Greater than 92% of the eosinophil 
SRS bioactivity was contributed by LTC4 and LTD4. The myotrophic properties of 
LTB4 and its isomers on lung parenchymal strips  (7) and guinea pig ileum (36) have 
only recently been recognized.  This property, which was  also observed during the 
course  of these  investigations,  may be  due  to  the  release  of thromboxanes  and 
prostaglandins induced by LTB4 in the bioassay system (7, 36). 
Thus, our findings suggest that eosinophils,  when appropriately stimulated, are a 
potent source of  leukotrienes. Eosinophilia is commonly  seen in patients with bronchial 
asthma (37), where a rise in eosinophil counts has been associated with a deterioration 
of pulmonary function and a concomitant increase in clinical symptoms (38). Eosin- 
ophils may play a causal role in asthma by their capacity to generate leukotrienes 
with  potent  SRS  activity.  Eosinophil  production  of leukotrienes,  which  increase 
vascular permeability and have potent chemotactic and smooth muscle contracting 
activity, may also be of great significance in the host defense against certain neoplasms 
and helminths, where eosinophils are found in greatly increased numbers. 
Summary 
Horse eosinophils purified to>98% generated slow reacting substance (SRS) when 
incubated  with  the  calcium  ionophore  A23187. On  a  per  cell  basis,  eosinophils 
generated four to five times the SRS produced by similarly treated horse neutrophils. 
Eosinophil  SRS  production  was  inhibited  by  5,8,11,14-eicosatetraynoic  acid  and 
augmented by indomethacin and arachidonic acid, suggesting that it was a product(s) 
of the lipoxygenase pathway of araehidonic acid metabolism. Compounds with SRS 
activity were purified by high-pressure  liquid chromatography (HPLC) and identified 
by ultraviolet spectra, spectral shift on treatment with lipoxygenase,  incorporation of 
[14C]arachidonic  acid,  gas chromatography-mass spectrometry, and comparison of 
retention times on HPLC to authentic standards. The eosinophil products character- 
ized were 5-(53, 12-(R)-dihydroxy-6-cis-8,  lO-trans-14-cis-eicosatetraenoic  acid (leuko- 
triene B4) and its 5-(53, 12-(R)-6-trans and 5-(53, 12-(S)-6-trans isomers, 5-(S)-hydroxy- 
6-(R)-S-glutathionyl-7,9-trans-11,14-cis-eicosatetraenoic  acid  (leukotriene C4)  and its 
11-trans isomer, and 5-(S)-hydroxy-6-(R)-S-cysteinylglycine-7,9-trans-11,14-cis-eicosa- 
tetraenoic acid (leukotriene D,). 
2 Henderson, W. R., J. Harley, A, S. Fauei, and S. J. Klebanoff. Unpublished results. 400  LEUKOTRIENE  GENERATION BY  EOSINOPHILS 
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